Modern immunotherapies such as PD-1/PD-L1 checkpoint inhibitors depend on robust anti-tumour T cell responses, yet many patients fail to respond.
A new Nature Communications study examines…
For a limited time, subscribe and SAVE 10% on your next purchase!
Sign Me Up!